[go: up one dir, main page]

NO20022125L - Pyrrolderivater som inhibitorer for fosfodiesterase VII - Google Patents

Pyrrolderivater som inhibitorer for fosfodiesterase VII

Info

Publication number
NO20022125L
NO20022125L NO20022125A NO20022125A NO20022125L NO 20022125 L NO20022125 L NO 20022125L NO 20022125 A NO20022125 A NO 20022125A NO 20022125 A NO20022125 A NO 20022125A NO 20022125 L NO20022125 L NO 20022125L
Authority
NO
Norway
Prior art keywords
inhibitors
pyrrole derivatives
phosphodiesterase vii
hal
phosphodiesterase
Prior art date
Application number
NO20022125A
Other languages
English (en)
Other versions
NO20022125D0 (no
Inventor
Hans Michael Eggenweiler
Rochus Jonas
Michael Wolf
Michael Gassen
Thomas Welge
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20022125L publication Critical patent/NO20022125L/no
Publication of NO20022125D0 publication Critical patent/NO20022125D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Forbindelser med formel (1) hvor R1 og R2 uavhengig av hverandre betyr H, A, OA, SA eller Hal; R3 betyr H eller A; R4 betyr A eller NH2; R5 betyr H, NH2, NHA eller NA2; A betyr alkyl med 1-10 C-atomer, alkenyl, sykloalkyl eller alkylensykloalkyl; Hal betyr F, Cl, Br eller I; samt deres fysiologisk akseptable salter og/eller solvater, som fosfodiesterase Vll-inhibitorer.
NO20022125A 1999-11-04 2002-05-03 Pyrrolderivater som inhibitorer for fosfodiesterase VII NO20022125D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953025A DE19953025A1 (de) 1999-11-04 1999-11-04 Pyrrolderivate als Phosphodiesterase VII-Hemmer
PCT/EP2000/010526 WO2001032618A1 (de) 1999-11-04 2000-10-25 Pyrrolderivate als phosphodiesterase vii-hemmer

Publications (2)

Publication Number Publication Date
NO20022125L true NO20022125L (no) 2002-05-03
NO20022125D0 NO20022125D0 (no) 2002-05-03

Family

ID=7927861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022125A NO20022125D0 (no) 1999-11-04 2002-05-03 Pyrrolderivater som inhibitorer for fosfodiesterase VII

Country Status (22)

Country Link
US (1) US6737436B1 (no)
EP (1) EP1230215B1 (no)
JP (1) JP2003513070A (no)
KR (1) KR20020063173A (no)
CN (1) CN1382122A (no)
AR (1) AR026351A1 (no)
AT (1) ATE339403T1 (no)
AU (1) AU782477B2 (no)
BR (1) BR0015334A (no)
CA (1) CA2389709C (no)
CZ (1) CZ20021440A3 (no)
DE (2) DE19953025A1 (no)
ES (1) ES2272331T3 (no)
HK (1) HK1049831A1 (no)
HU (1) HUP0203288A3 (no)
MX (1) MXPA02004440A (no)
NO (1) NO20022125D0 (no)
PL (1) PL355099A1 (no)
RU (1) RU2002113750A (no)
SK (1) SK5952002A3 (no)
WO (1) WO2001032618A1 (no)
ZA (1) ZA200204433B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
ATE375347T1 (de) 2001-12-13 2007-10-15 Asubio Pharma Co Ltd Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
DE10226420A1 (de) * 2002-06-13 2004-01-15 Eucro European Contract Research Gmbh & Co Kg Verfahren zur Behandlung der Artherosklerose
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
EP2433943B1 (en) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101917992A (zh) 2007-03-27 2010-12-15 奥默罗斯公司 用于治疗运动障碍的pde7抑制剂的用途
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
EP4275752A3 (en) 2010-11-08 2024-02-21 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CA3069432A1 (en) 2017-07-12 2019-01-17 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
CN119768172A (zh) 2022-08-18 2025-04-04 米托迪治愈有限责任公司 具有磷酸二酯酶-7抑制活性的治疗剂在治疗和预防与慢性疲劳、衰竭和/或劳累不耐受有关的疾病中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE154827C (no)
DD154827A1 (de) * 1980-11-28 1982-04-21 Karl Gewald Verfahren zur herstellung von azofarbstoffen aus substituierten 3-aminopyrrolen
ES2208964T3 (es) * 1996-12-10 2004-06-16 G.D. SEARLE & CO. Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion.

Also Published As

Publication number Publication date
HUP0203288A2 (hu) 2003-01-28
BR0015334A (pt) 2002-07-09
ES2272331T3 (es) 2007-05-01
ATE339403T1 (de) 2006-10-15
CA2389709A1 (en) 2001-05-10
DE19953025A1 (de) 2001-05-10
AU782477B2 (en) 2005-08-04
EP1230215A1 (de) 2002-08-14
AU1387301A (en) 2001-05-14
AR026351A1 (es) 2003-02-05
JP2003513070A (ja) 2003-04-08
CA2389709C (en) 2009-02-10
HK1049831A1 (zh) 2003-05-30
RU2002113750A (ru) 2004-01-10
MXPA02004440A (es) 2004-09-10
WO2001032618A1 (de) 2001-05-10
ZA200204433B (en) 2003-09-03
EP1230215B1 (de) 2006-09-13
CZ20021440A3 (cs) 2002-07-17
NO20022125D0 (no) 2002-05-03
DE50013473D1 (de) 2006-10-26
CN1382122A (zh) 2002-11-27
US6737436B1 (en) 2004-05-18
SK5952002A3 (en) 2002-09-10
HUP0203288A3 (en) 2003-12-29
KR20020063173A (ko) 2002-08-01
PL355099A1 (en) 2004-04-05

Similar Documents

Publication Publication Date Title
NO20022125L (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
DK1389617T3 (da) Heterocyclisk forbindelse og antitumormiddel indeholdende denne som den aktive bestanddel
CA2432713A1 (en) Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
YU57603A (sh) Inhibitori fosfodiesteraze 4
AP2001002046A0 (en) Heterocyclic compounds as inhibitors of rotamase enzymes.
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
MX9800718A (es) Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida.
NO20022232L (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
NO20022124L (no) Imidazopyridinderivater som fosfodiesterase VII-inhibitorer
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
WO2002028844A1 (en) Thiazole or oxazole derivatives
ID26622A (id) Senyawa-senyawa pengganti 2-benzylamino-2-phenyl-acetamide
EP1304324A4 (en) SEROTONIN RECOVERY INHIBITORS
MY117159A (en) Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation.
EP1357124A4 (en) HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS
NO995289D0 (no) Benzimidazol-derivater
DK1303514T3 (da) Fremgangsmåde til fremstilling af azacycloalkanoylaminothiazoler
DK0812835T3 (da) Optisk aktive thiazolidinonderivater
EP0407621A4 (en) Benzothiazole derivatives
ES2190781T3 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
TR200103215T2 (tr) 6-[[(Aril ve heteroaril)oksi]metil]naftalin-2-karboksimidamid türevleri, bunların hazırlanması ve terapötik uygulamaları
FI902775A0 (fi) Aryloxi-, aryltio-, heteroaryloxi-, heteroaryltio-alkylenderivat av aminer.
ES2206296T3 (es) Derivados de tienopiranocarboxamida.
PL321309A1 (en) Novel bis-imide compounds, method of obtaining them and pharmaceutic compositions containing such compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application